Organovo Holdings, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
VivoSim Labs Director Douglas Cohen reported the acquisition of 15,000 restricted stock units, vesting by January 2027.
VivoSim Labs' Executive Chairman, Keith Murphy, acquired 15,000 restricted stock units, increasing his beneficial ownership to 26,053 shares.
VivoSim Labs director Alison Milhous received a grant of 15,000 restricted stock units, which will vest by early 2027.
VivoSim Labs Director David Gobel received a grant of 15,000 restricted stock units, vesting in early 2027 or upon the next annual meeting.
VivoSim Labs Director Adam Stern reported the acquisition of 15,000 restricted stock units, bringing his total beneficial ownership to 19,899 shares.
VivoSim Labs' Chief Scientific Officer, Amar Akhtar Sethi, was granted 53,500 stock options with an exercise price of $2.19, vesting over four years.
VivoSim Labs director David Gobel sold 3,266 shares of common stock at $2.2351 per share, reducing his direct beneficial ownership to zero.
VivoSim Labs' Chief Commercial Officer, Tony Serge Lialin, was granted 40,000 stock options with a $1.78 exercise price, vesting over four years.
Director David Gobel acquired 19,607 shares of Organovo Holdings through restricted stock units on August 7, 2024.
Director Douglas Jay Cohen acquired 19,607 shares of Organovo Holdings, Inc. through restricted stock units.
Alison Tjosvold Milhous, a director at Organovo Holdings, acquired 19,607 shares of common stock through restricted stock units on August 7, 2024.
Director Adam Stern acquired 19,607 restricted stock units in Organovo Holdings, Inc. on August 7, 2024.
Director Vaidehi Joshi acquired 19,607 shares of Organovo Holdings, Inc. on August 7, 2024.
Keith Murphy, Executive Chairman of Organovo Holdings, reports acquisition of restricted stock units and options.